Enjoy complimentary customisation on priority with our Enterprise License!
The antibody drug conjugates (ADC) market size is forecast to increase by USD 9.95 billion at a CAGR of 15.06% between 2023 and 2028. The antibody drug conjugates (ADCs) market is experiencing significant growth due to the increasing prevalence of cancer and other diseases, leading to heightened demand for effective therapeutic options. ADCs, which consist of monoclonal antibodies conjugated with cytotoxic drugs via a linker, offer targeted therapy by binding to surface antigens on tumor cells. This targeted approach reduces the side effects associated with traditional chemotherapy. However, the high development costs for ADCs pose a challenge to market growth. Multi-specific antibodies, a newer class of ADCs, are gaining attention due to their ability to target multiple antigens on tumor cells, enhancing therapeutic efficacy. The adoption and development of ADCs and multi-specific antibodies are expected to continue, driven by the need for more effective and targeted cancer treatments.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.